Oral Propranolol Decreases Intestinal Permeability in Patients With Cirrhosis: Another Protective Mechanism Against Bleeding?

β‐Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta‐analysis

Senzolo, M., Cholongitas, E., Burra, P., Leandro, G., Thalheimer, U., Patch, D., & Burroughs, A. K. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02038.x · Cited by 241 · see citing works

How to Prevent Varices From Bleeding: Shades of Grey—The Case for Nonselective β Blockers

Thalheimer, U., Bosch, J., & Burroughs, A. K. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.10.028 · Cited by 80 · see citing works

Intestinal permeability in cirrhotic patients with and without ascites

Kalaitzakis, E., Johansson, J., Bjarnason, I., & Bjornsson, E. S. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520510024278 · Cited by 50 · see citing works

Influence of portal pressure change on intestinal permeability in patients with portal hypertension.

Xu, W., Wu, X., & Li, J. (2002) · PubMed · Cited by 33 · see citing works

Gastric permeability to sucrose is increased in portal hypertensive gastropathy

Giofré, M. R., Meduri, G., Pallio, S., Calandra, S., Magnano, A., Niceforo, D., Cinquegrani, M., Leo, V. D., Mazzon, E., Sturniolo, G. C., et al. (2000) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200012050-00009 · Cited by 29 · see citing works

Propranolol treatment normalizes gastric permeability in portal hypertensive gastropathy

Giofré, M. R., Presti, M. L., Herpell, J., & Fries, W. (2001) · Digestive and Liver Disease · doi:10.1016/s1590-8658(01)80239-5 · Cited by 1 · see citing works

4 OC Propranolol decreases gastric permeability through a reduction of TNF production in a rat model of portal hypertensive gastropathy (PHG)

Herpell, J., Giofré, M. R., RASO, A. F., Presti, M. L., Sturniolo, G. C., & Fries, W. (2002) · Digestive and Liver Disease · doi:10.1016/s1590-8658(02)90170-2 · Cited by 1 · see citing works

Changes of Intestinal Functions in Liver Cirrhosis

Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,820 · see citing works

The gut microbiome and liver cancer: mechanisms and clinical translation

Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634 · see citing works

Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis

Reiberger, T., Ferlitsch, A., Payer, B. A., Mandorfer, M., Heinisch, B. B., Hayden, H., Lammert, F., Trauner, M. A., Peck‐Radosavljevic, M., & Vogelsang, H. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.011 · Cited by 328 · see citing works

Gut–liver axis, cirrhosis and portal hypertension: the chicken and the egg

Arab, J. P., Martín‐Mateos, R., & Shah, V. H. (2017) · Hepatology International · doi:10.1007/s12072-017-9798-x · Cited by 229 · see citing works

Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure

Trebicka, J., Bork, P., Krag, A. A., & Arumugam, M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00376-3 · Cited by 203 · see citing works

Altered intestinal tight junctions’ expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability

Assimakopoulos, S. F., Tsamandas, A. C., Tsiaoussis, G. I., Karatza, E., Triantos, C. K., Vagianos, C., Spiliopoulou, I. T., Kaltezioti, V., CHARONIS, A. S., Nikolopoulou, V. N., et al. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02609.x · Cited by 166 · see citing works

Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target

Miele, L., Marrone, G., Lauritano, C., Cefalo, C., Gasbarrini, A., Day, C., & Grieco, A. (2012) · Current Pharmaceutical Design · doi:10.2174/1381612811319290011 · Cited by 131 · see citing works

Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature

Pijls, K. E., Jonkers, D. M. A. E., Elamin, E. E., Masclee, A., & Koek, G. H. (2013) · Liver International · doi:10.1111/liv.12271 · Cited by 123 · see citing works

The chronic use of beta‐blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis

Merli, M., Lucidi, C., Gregorio, V. D., Giannelli, V., Giusto, M., Ceccarelli, G., Riggio, O., & Venditti, M. (2014) · Liver International · doi:10.1111/liv.12593 · Cited by 95 · see citing works

New Developments in Managing Variceal Bleeding

Ibrahim, M., Mostafa, I., & Deviere, J. M. E. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.02.023 · Cited by 85 · see citing works

Splanchnic sympathectomy prevents translocation and spreading of E coli but not S aureus in liver cirrhosis

Worlicek, M., Knebel, K., Linde, H. ‐., Moleda, L., Schölmerich, J., Straub, R. H., & Wiest, R. (2010) · Gut · doi:10.1136/gut.2009.185413 · Cited by 61 · see citing works

Intestinal permeability in a patient with liver cirrhosis

Aguirre-Valádez, J., Rivera-Espinosa, L., Méndez-Guerrero, O., Chávez-Pacheco, J. L., Juárez, I. G., & Torre, A. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s115902 · Cited by 50 · see citing works

Targeting the Gut–Liver Axis in Cirrhosis: Antibiotics and Non-Selective β-Blockers

Madsen, B. S., Havelund, T., & Krag, A. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0044-1 · Cited by 38 · see citing works

Clinical and Pathophysiological Consequences of Alterations in the Microbiome in Cirrhosis

Macnaughtan, J., & Jalan, R. (2015) · The American Journal of Gastroenterology · doi:10.1038/ajg.2015.313 · Cited by 38 · see citing works

Intestinal mucosal proliferation, apoptosis and oxidative stress in patients with liver cirrhosis

Assimakopoulos, S. F., Tsamandas, A. C., Tsiaoussis, G. I., Karatza, E., Zisimopoulos, D., Maroulis, I. C., Kontogeorgou, E., Georgiou, C. D., Scopa, C. D., & Thomopoulos, K. C. (2013) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31369-9 · Cited by 32 · see citing works

Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma

Yu, Q., Wu, L., Ji, J., Feng, J., Dai, W., Li, J., Wu, J., & Guo, C. (2020) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s277870 · Cited by 27 · see citing works

Novel therapeutics for portal hypertension and fibrosis in chronic liver disease

Guixé‐Muntet, S., Zhu, C., Xie, W., & Gracia‐Sancho, J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107626 · Cited by 25 · see citing works

The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS).

Benten, D., Wiesch, J. S. Z., Sydow, K., Koops, A., Buggisch, P., Böger, R. H., Gaydos, C. A., Won, H., Franco, V., Lohse, A. W., et al. (2011) · BMC Gastroenterology · doi:10.1186/1471-230x-11-107 · Cited by 24 · see citing works

Could antioxidants be the “magic pill” for cirrhosis-related complications? A pathophysiological appraisal

Assimakopoulos, S. F., Gogos, C. A., & Karatza, C. L. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.05.034 · Cited by 24 · see citing works

The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status

Stojić, J., Kukla, M., & Grgurević, I. (2023) · Diagnostics · doi:10.3390/diagnostics13182960 · Cited by 21 · see citing works

The role of gut barrier dysfunction in postoperative complications in liver transplantation: pathophysiological and therapeutic considerations

Assimakopoulos, S. F., Bhagani, S. R., Aggeletopoulou, I., Tsounis, E. P., & Tsochatzis, E. A. (2024) · Infection · doi:10.1007/s15010-024-02182-4 · Cited by 20 · see citing works

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors

Wu, L. Y., Hyfte, G. V., Özbek, U., Reincke, M., Gampa, A., Mohamed, Y. I., Nishida, N., Wietharn, B., Amara, S., Lee, P., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1128569 · Cited by 18 · see citing works

Portal Hypertension in Malnutrition and Sarcopenia in Decompensated Cirrhosis—Pathogenesis, Implications and Therapeutic Opportunities

Terbah, R., Testro, A., Gow, P. J., Majumdar, A., & Sinclair, M. J. (2023) · Nutrients · doi:10.3390/nu16010035 · Cited by 18 · see citing works

Is hydrophobia necessary for the hepatologist prescribing nonselective beta-blockers in cirrhosis?

Senzolo, M., Nadal, E., Cholongitas, Ε., & Burroughs, A. K. (2011) · Hepatology · doi:10.1002/hep.24176 · Cited by 16 · see citing works

Hepatic Encephalopathy in Cirrhotic Patients and Risk of Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta‐Analysis

Feng, X., Li, X., Zhang, X., Chen, W., Tian, Y., Yang, Q., Yang, Y., Pan, H., & Jiang, Z. (2022) · BioMed Research International · doi:10.1155/2022/2469513 · Cited by 13 · see citing works

Non-Selective Beta-Blockers Decrease Infection, Acute Kidney Injury Episodes, and Ameliorate Sarcopenic Changes in Patients with Cirrhosis: A Propensity-Score Matching Tertiary-Center Cohort Study

Li, T., Liu, C.-W., Huang, C., Tsai, Y.-L., Huang, S., Yang, Y., Tsai, C., Hou, M., & Lin, H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112244 · Cited by 11 · see citing works

MR Measures of Small Bowel Wall T2 Are Associated With Increased Permeability

Scott, R. A., Williams, H. G., Hoad, C. L., Alyami, A. S., Ortori, C. A., Grove, J. I., Marciani, L., Moran, G. W., Spiller, R. E., Menys, A., et al. (2020) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27463 · Cited by 10 · see citing works

Duodenal Morphometry and Small Bowel Permeability in Children With Portal Hypertension

Borkar, V., Poddar, U., Kumari, N., Singh, S., Roy, R., & Yachha, S. K. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000578 · Cited by 11 · see citing works

Preventing the progression of cirrhosis to decompensation and death

Villanueva, C., Tripathi, D., & Bosch, J. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01031-x · Cited by 10 · see citing works

B-Blockers in Liver Cirrhosis: A Wonder Drug for Every Stage of Portal Hypertension? A Narrative Review

Karagiannakis, D. S., Karakousis, N. D., & Ανδρουτσάκος, Θ. (2023) · Biomedicines · doi:10.3390/biomedicines12010057 · Cited by 8 · see citing works

Influence of Gut–Liver Axis on Portal Hypertension in Advanced Chronic Liver Disease: The Gut Microbiome as a New Protagonist in Therapeutic Management

Santopaolo, F., Coppola, G., Giuli, L., Gasbarrini, A., & Ponziani, F. R. (2022) · Microbiology Research · doi:10.3390/microbiolres13030038 · Cited by 7 · see citing works

Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy

Lee, P., Chen, Y., Chou, Y., Lee, K., Chen, P., Kao, W., Huang, Y., Huo, T., Lin, H., Hou, M., et al. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001511 · Cited by 5 · see citing works

Association Between Bowel Wall Thickening and Long-Term Outcomes in Decompensated Liver Cirrhosis

Wang, X., Ding, M., Wang, W., Zheng, X., Philips, C. A., Méndez‐Sánchez, N., Jin, H., & Qi, X. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02690-z · Cited by 3 · see citing works

The Gut Microbiome and Cirrhosis: Basic Aspects

Wiest, R. (2015) · Springer eBooks · doi:10.1007/978-3-319-23018-4_18 · Cited by 1 · see citing works

On the role of intestinal hyperpermeability in complications of cirrhosis

Assimakopoulos, S. F. (2012) · Liver International · doi:10.1111/liv.12094 · Cited by 1 · see citing works

Modulation of the gut-liver axis in cirrhosis with activated carbon

Macnaughtan, J. (2017) · UCL Discovery (University College London)

The effect of propranolol on gastrointestinal motility and permeability in patients with cirrhosis and significant portal hypertension

Xirouchakis, E., Kranidioti, H., Hadziyanni, E., Κourikou, A., Reppas, C. I., Vertzoni, M., Papadopoulos, N., Deutsch, M. J., Papatheodoridis, G., & Manolakopoulos, S. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03483-6 · Cited by 5 · see citing works

THU-145-YI Propranolol reverses splanchnic β-adrenergic induced small intestinal barrier disruption stabilizing gut-liver axis in experimental cirrhosis

Castillo, E., Felber, M., Paule, L., Muñoz, L., Miranda, A., Juanola, O., Alonso, M. P., de Dios, O., del Campo, R., Pastor, Ó., et al. (2025) · Journal of Hepatology · doi:10.1016/s0168-8278(25)00623-3

Allopurinol, oxidative stress and intestinal permeability in patients with cirrhosis: an open‐label pilot study

Spahr, L., Bresson‐Hadni, S., Amann, P., Kern, I., Golaz, O., Frossard, J., & Hadengue, A. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01382.x · Cited by 40 · see citing works

Long-term effects of oral propranolol on splanchnic-and systemic haemodynamics in patients with cirrhosis and oesophageal varices

Bendtsen, F., Henriksen, J. H., & Sørensen, T. I. A. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)91357-m · Cited by 4 · see citing works

Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy*1

Panés, J. (1993) · Hepatology · doi:10.1016/0270-9139(93)90079-3 · Cited by 5 · see citing works